CTLA4 and uveal melanoma: Heppt et al. described that Eastern Cooperative Oncology Group (ECOG) PS, high LDH, high CRP, and REC < 1.5% were significantly associated with poor survival in metastatic uveal melanoma patients treated with either anti-PD-1 antibody monotherapy or a combination of anti-PD-1 and anti-CTLA-4 antibodies [2].